Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0707L |
Cyclophosphamide
|
DNA Alkylator/Crosslinker; DNA; MRP | DNA Damage/DNA Repair; Immunology/Inflammation |
Cyclophosphamide 是一种烷化剂,具有抗肿瘤及免疫抑制活性,用于治疗多种癌症。 | |||
T0707 |
Cyclophosphamide hydrate
环磷酰胺一水物,Cyclophosphamide monohydrate,环磷酰胺水合物 |
DNA Alkylator/Crosslinker; DNA; MRP | DNA Damage/DNA Repair; Immunology/Inflammation |
Cyclophosphamide hydrate 是一种 DNA 烷化剂,一种 DNA 合成抑制剂。Cyclophosphamide hydrate 具有抗肿瘤活性、免疫抑制活性等。 | |||
T35643 |
4-hydroperoxy Cyclophosphamide
4-hydroperoxy Cyclophosphamide,4-OOH-CY |
||
4-hydroperoxy Cyclophosphamide (4-OOH-CY) is the active metabolite form of the prodrug Cyclophosphamide. 4-OOH-CY crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS).[1] Formulations containing the prodrug Cyclophosphamide are used to treat lymphomas and autoimmune disorders.[2],[3] | |||
T35645 |
4-oxo Cyclophosphamide
|
||
4-oxo Cyclophosphamide is an inactive metabolite of the alkylating agent cyclophosphamide .1,2It is formed from cyclophosphamide through a 4-hydroxycyclophosphamide intermediate by aldehyde dehydrogenases.2 1.Struck, R.F., Kirk, M.C., Mellett, L.B., et al.Urinary metabolites of the antitumor agent cyclophosphamideMol. Pharmacol.7(5)519-529(1971) 2.de Jonge, M.E., Huitema, A.D.R., Rodenhuis, S., et al.Clinical pharmacokinetics of cyclophosphamideClin. Pharmacokinet.44(11)1135-1164(2005) | |||
T1414 |
Sodium 2-mercaptoethanesulfonate
Mitexan,美司那,美司钠,Uromitexan,Mesna,Mesnum,Mesnex |
Others | Others |
Sodium 2-mercaptoethanesulfonate (Uromitexan) 是一种抗氧化剂,具有细胞保护作用。它可用于减轻由环磷酰胺引起的出血性膀胱炎。它广泛用作抗化学疗法毒性的全身保护剂。 | |||
T38410 |
Phosphoramide mustard
|
DNA Alkylation; Drug Metabolite | DNA Damage/DNA Repair; Metabolism |
Phosphoramide mustard 是环磷酰胺的毒性代谢物物,具有抗癌活性且对卵巢具有毒性,可诱导 DNA 损伤。 | |||
T1055 |
Ifosfamide
NSC109724,Isophosphamide,异环磷酰胺 |
DNA Alkylator/Crosslinker; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
Ifosfamide (NSC-109724) 是一种烷化剂,具有抗肿瘤活性。它烷基化并形成 DNA 交联,从而防止 DNA 链分离和 DNA 复制。它是一种前药,必须通过肝微粒体酶的羟基化来激活。 | |||
T37108 |
Carboxyphosphamide
|
||
Carboxyphosphamide is an inactive metabolite of the alkylating agent cyclophosphamide .1It is formed from cyclophosphamideviaoxidation of the intermediate metabolite aldophosphamide by aldehyde dehydrogenase. 1.Manthey, C.L., and Sladek, N.E.Kinetic characterization of the catalysis of activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenasesBiochem. Pharmacol.37(14)2781-2790(1988)" | |||
T29845 |
Alcophosphamide
NSC 153182,Hydroxyphosphamide |
||
Alcophosphamide is a urinary metabolite of cyclophosphamide which may be used in proteomics research. | |||
T24102 |
GR-203040 HCl
GR 203040,GR-203040 hydrochloride,GR-203040,GR203040 |
||
GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. GR-203040 is a selective NK1 receptor antagonist. | |||
T25723 |
L-Ifosfamide
(+)-Ifosfamide |
||
L-Ifosfamide is nitrogen mustard, a chemotherapeutic antineoplastic, and more precisely an alkylating agent structural analog of cyclophosphamide with respect to which presents some differences regard to the antitumor activity and spectrum. | |||
T68434 | Mafosfamide | ||
Mafosfamide is a synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. | |||
T68592 |
Mafosfamide sodium
|
||
Mafosfamide is a synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. | |||
T70304 |
CI-898 HCl
|
||
CI-898 HCl is a lipophilic antifolate inhibitor of dihydrofolate reductase (DHFR). It has enhanced binding to DHFR in the presence of the cofactor NADPH. Cl-898 HCl inhibits cell growth and halts the cell cycle at the G1/S phase in L1210 mouse lymphocytic leukemia cells and is active against methotrexate-resistant cancer cell lines. It also enhances the activity of doxorubicin, cyclophosphamide, and 6-thioguanine (6-TG) in mice with advanced stage P338 leukemia. | |||
T36701 | Phosphoramide mustard (cyclohexanamine) | ||
Phosphoramide mustard cyclohexanamine is the major metabolite for Cyclophosphamide , with anticancer activitiy. Phosphoramide mustard cyclohexanamine induces DNA adduct formation in ovarian granulosa cells, induces DNA damage and elicits the ovarian DNA repair response[1][2]. Phosphoramide mustard cyclohexanamine causes cytotoxicity through forming cross-linked DNA adducts which inhibit DNA strand separation during replication[1].Phosphoramide mustard cyclohexanamine destroys rapidly dividing ce... | |||
T63464 | ERCC1-XPF-IN-1 | ||
ERCC1-XPF-IN-1 是有效的、高亲和力的 ERCC1-XPF 抑制剂 (IC50: 0.49 μM)。ERCC1-XPF-IN-1 能够抑制 CPDs 的去除,降低环磷酰胺对结直肠癌细胞的毒性,提高了 UV 辐射的细胞毒性作用,阻碍 DNA 修复。 | |||
T71549 | RKS-262 | ||
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several... |